These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18929815)

  • 1. Treatment and prophylaxis of cardiac allograft vasculopathy.
    Wang SS
    Transplant Proc; 2008 Oct; 40(8):2609-10. PubMed ID: 18929815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation.
    Sánchez Lázaro IJ; Almenar Bonet L; Moro López J; Sánchez Lacuesta E; Martínez-Dolz L; Agüero Ramón-Llín J; Andrés Lalaguna L; Cano Pérez O; Ortiz Martínez V; Buendía Fuentes F; Salvador Sanz A
    Transplant Proc; 2008 Nov; 40(9):3056-7. PubMed ID: 19010192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation signal inhibitors and cardiac allograft vasculopathy.
    Raichlin E; Kushwaha SS
    Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac allograft vasculopathy: recent developments.
    Schmauss D; Weis M
    Circulation; 2008 Apr; 117(16):2131-41. PubMed ID: 18427143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
    Valantine H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H; Kobashigawa J; Starling RC; Valantine H; Mancini D
    Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication management of cardiac allograft vasculopathy after heart transplantation.
    Hollis IB; Reed BN; Moranville MP
    Pharmacotherapy; 2015 May; 35(5):489-501. PubMed ID: 26011142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac allograft vasculopathy: current concepts and treatment.
    Waller J; Brook NR; Nicholson ML
    Transpl Int; 2003 Jun; 16(6):367-75. PubMed ID: 12756523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allograft vascular disease: comparison of heart and other grafted organs.
    Radio S; Wood S; Wilson J; Lin H; Winters G; McManus B
    Transplant Proc; 1996 Feb; 28(1):496-9. PubMed ID: 8644326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The University of California at Los Angeles heart transplantation experience.
    Kobashigawa JA; Laks H; Wu G; Patel J; Moriguchi J; Hamilton M; Fonarow G; Fishbein M; Ardehali A
    Clin Transpl; 2005; ():173-85. PubMed ID: 17424734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence that NK cells may contribute to the development of cardiac allograft vasculopathy.
    Uehara S; Chase CM; Colvin RB; Russell PS; Madsen JC
    Transplant Proc; 2005; 37(1):70-1. PubMed ID: 15808550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a combined heart and carotid artery transplant model to investigate the impact of acute rejection on cardiac allograft vasculopathy.
    Soleimani B; Fu F; Lake P; Shi VC
    J Heart Lung Transplant; 2008 Apr; 27(4):450-6. PubMed ID: 18374883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The continuing challenge of cardiac transplant arteriosclerosis.
    Weis M; Meiser BM; Reichart B; von Scheidt W
    Cardiologia; 1998 Aug; 43(8):777-87. PubMed ID: 9808867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation.
    Mahle WT; Vincent RN; Berg AM; Kanter KR
    J Heart Lung Transplant; 2005 Jan; 24(1):63-6. PubMed ID: 15653381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
    Delgado JF; Manito N; Segovia J; Almenar L; Arizón JM; Campreciós M; Crespo-Leiro MG; Díaz B; González-Vílchez F; Mirabet S; Palomo J; Roig E; de la Torre JM
    Transplant Rev (Orlando); 2009 Apr; 23(2):69-79. PubMed ID: 19298938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac allograft vasculopathy after cardiac transplantation and hormone therapy: positive effects?
    Lange V; Renner A; Sagstetter M; Harms H; Elert O
    Transplantation; 2006 Jul; 82(2):234-40. PubMed ID: 16858287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma".
    Valantine HA
    Transplantation; 2003 Sep; 76(6):891-9. PubMed ID: 14508350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intimal fibrosis in human cardiac allograft vasculopathy.
    Huibers M; De Jonge N; Van Kuik J; Koning ES; Van Wichen D; Dullens H; Schipper M; De Weger R
    Transpl Immunol; 2011 Sep; 25(2-3):124-32. PubMed ID: 21782945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.
    Potena L; Fearon WF; Sydow K; Holweg C; Luikart H; Chin C; Weisshaar D; Mocarski ES; Lewis DB; Valantine HA; Cooke JP
    Transplantation; 2008 Mar; 85(6):827-33. PubMed ID: 18360263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
    Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
    Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.